Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

Lorraine Tafra, Zandra Cheng, Joseph Uddo, Mary B. Lobrano, William Stein, Wendie A. Berg, Edward Levine, Irving N. Weinberg, Deepa Narayanan, Eric Ross, David Beylin, Stephen Yarnall, Rochelle Keen, Kristen Sawyer, Jack Van Geffen, Rita L. Freimanis, Edward Staab, Lee P. Adler, Judy Lovelace, Perry Shen & 2 others John Stewart, Sergei Dolinsky

Research output: Contribution to journalArticle

Abstract

Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

Original languageEnglish (US)
Pages (from-to)628-632
Number of pages5
JournalAmerican Journal of Surgery
Volume190
Issue number4
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Mammography
Clinical Trials
Electrons
Breast Neoplasms
Segmental Mastectomy
Breast
Prospective Studies
Equipment and Supplies
Multicenter Studies
Pathology
Neoplasms

Keywords

  • 18F-fluorodeoxyglucose
  • Breast cancer
  • Positron-emission tomography

ASJC Scopus subject areas

  • Surgery

Cite this

Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. / Tafra, Lorraine; Cheng, Zandra; Uddo, Joseph; Lobrano, Mary B.; Stein, William; Berg, Wendie A.; Levine, Edward; Weinberg, Irving N.; Narayanan, Deepa; Ross, Eric; Beylin, David; Yarnall, Stephen; Keen, Rochelle; Sawyer, Kristen; Van Geffen, Jack; Freimanis, Rita L.; Staab, Edward; Adler, Lee P.; Lovelace, Judy; Shen, Perry; Stewart, John; Dolinsky, Sergei.

In: American Journal of Surgery, Vol. 190, No. 4, 10.2005, p. 628-632.

Research output: Contribution to journalArticle

Tafra, L, Cheng, Z, Uddo, J, Lobrano, MB, Stein, W, Berg, WA, Levine, E, Weinberg, IN, Narayanan, D, Ross, E, Beylin, D, Yarnall, S, Keen, R, Sawyer, K, Van Geffen, J, Freimanis, RL, Staab, E, Adler, LP, Lovelace, J, Shen, P, Stewart, J & Dolinsky, S 2005, 'Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer', American Journal of Surgery, vol. 190, no. 4, pp. 628-632. https://doi.org/10.1016/j.amjsurg.2005.06.029
Tafra, Lorraine ; Cheng, Zandra ; Uddo, Joseph ; Lobrano, Mary B. ; Stein, William ; Berg, Wendie A. ; Levine, Edward ; Weinberg, Irving N. ; Narayanan, Deepa ; Ross, Eric ; Beylin, David ; Yarnall, Stephen ; Keen, Rochelle ; Sawyer, Kristen ; Van Geffen, Jack ; Freimanis, Rita L. ; Staab, Edward ; Adler, Lee P. ; Lovelace, Judy ; Shen, Perry ; Stewart, John ; Dolinsky, Sergei. / Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. In: American Journal of Surgery. 2005 ; Vol. 190, No. 4. pp. 628-632.
@article{fd25be82472542faa4a6d90066ceb268,
title = "Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer",
abstract = "Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89{\%}, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75{\%}) patients with positive margins and 100{\%} (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.",
keywords = "18F-fluorodeoxyglucose, Breast cancer, Positron-emission tomography",
author = "Lorraine Tafra and Zandra Cheng and Joseph Uddo and Lobrano, {Mary B.} and William Stein and Berg, {Wendie A.} and Edward Levine and Weinberg, {Irving N.} and Deepa Narayanan and Eric Ross and David Beylin and Stephen Yarnall and Rochelle Keen and Kristen Sawyer and {Van Geffen}, Jack and Freimanis, {Rita L.} and Edward Staab and Adler, {Lee P.} and Judy Lovelace and Perry Shen and John Stewart and Sergei Dolinsky",
year = "2005",
month = "10",
doi = "10.1016/j.amjsurg.2005.06.029",
language = "English (US)",
volume = "190",
pages = "628--632",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer

AU - Tafra, Lorraine

AU - Cheng, Zandra

AU - Uddo, Joseph

AU - Lobrano, Mary B.

AU - Stein, William

AU - Berg, Wendie A.

AU - Levine, Edward

AU - Weinberg, Irving N.

AU - Narayanan, Deepa

AU - Ross, Eric

AU - Beylin, David

AU - Yarnall, Stephen

AU - Keen, Rochelle

AU - Sawyer, Kristen

AU - Van Geffen, Jack

AU - Freimanis, Rita L.

AU - Staab, Edward

AU - Adler, Lee P.

AU - Lovelace, Judy

AU - Shen, Perry

AU - Stewart, John

AU - Dolinsky, Sergei

PY - 2005/10

Y1 - 2005/10

N2 - Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

AB - Background: High-resolution positron-emission mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods: In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results: The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion: The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.

KW - 18F-fluorodeoxyglucose

KW - Breast cancer

KW - Positron-emission tomography

UR - http://www.scopus.com/inward/record.url?scp=24944511980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944511980&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2005.06.029

DO - 10.1016/j.amjsurg.2005.06.029

M3 - Article

VL - 190

SP - 628

EP - 632

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -